Evidence map›Paper›PMID 37305156›Full record

ArticleCurrent opinion in physiology2023

Endothelial-to-mesenchymal transition: advances and controversies.

Michael Simons

Abstract read
In one paragraph

Article in Current opinion in physiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. ILK-Dependent Modulation of DPP4 Prevents Progression of Calcific Aortic Valve Disease.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  2. Article
  3. Review
  4. Endothelial to mesenchymal transition: a central mechanism in diabetes-induced vascular pathology.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Michael SimonsYale Cardiovascular Research Center, Department of Internal Medicine, 300 George Street, New Haven, CT 06511.

Funding

Surgery / Physiology CoreP01HL107205 · NHLBI · YALE UNIVERSITY · PI SUAREZ, YAJAIRA · 2012 to 2022
$18.8M
Endothelial-to-mesenchyma transition and atherosclerosisR01HL135582 · NHLBI · YALE UNIVERSITY · PI SCHWARTZ, MARTIN A, SIMONS, MICHAEL · 2017 to 2024
$6.6M
Vascular smooth muscle cell heterogeneity and diseaseR01HL152197 · NHLBI · YALE UNIVERSITY · PI SIMONS, MICHAEL, TELLIDES, GEORGE · 2021 to 2024
$3.3M
Smooth Muscle Cell Proliferation and Degradative Phenotype in Thoracic Aorta Aneurysm and DissectionR01HL146723 · NHLBI · YALE UNIVERSITY · PI HUMPHREY, JAY D., TELLIDES, GEORGE · 2019 to 2022
$2.9M
Acetate and Endothelial PathobiologyR01HL167014 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Zoltan P Arany, Michael Simons · 2023 to 2026
$2.8M
NHLBI NIH HHS P01 HL107205NHLBI NIH HHS R01 HL135582NHLBI NIH HHS R01 HL146723NHLBI NIH HHS R01 HL152197NHLBI NIH HHS R01 HL167014
6 · The paper itself

Abstract

Endothelial-to-mesenchymal transition (EndMT) is a physiological process that is equally important during development and under certain pathological conditions in adult tissues. The last decade has witnessed a remarkable explosion of information about EndMT from molecular mechanisms responsible for its development to its role in various disease processes. The emerging picture is that of a complex set of interactions that underly pathophysiological basis of some of the most deadly and intractable diseases. This mini review brings together recent advances and attempts to present a unified view of this complex field.

Indexed as

atherosclerosisCCMEndMTendothelial cellsFGFhypertensionPAHpulmonarysclerodermasmooth muscle cellssystemic sclerosisTGF

Identifiers

PMID37305156
PMCPMC10249652

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.